Scientific Sessions 2025  /  Annual Lipid Update 2025  /  What LDL-C (or ApoB) level should we be targeting? And how ASCVD history inform LDL-C targets?
Logo

American Heart Association

  31
  0

Final ID:

What LDL-C (or ApoB) level should we be targeting? And how ASCVD history inform LDL-C targets?

  • Khera, Amit  ( UT Southwestern , Dallas , Texas , United States )
  • Joshi, Parag  ( UT Southwestern Medical Center , Dallas , Texas , United States )
    • Author Disclosures:
    Amit Khera: DO NOT have relevant financial relationships | Parag Joshi: DO have relevant financial relationships ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Consultant:New Amsterdam Pharma:Past (completed) ; Consultant:Kaneka:Past (completed) ; Consultant:Novartis:Past (completed) ; Research Funding (PI or named investigator):Kaneka:Past (completed) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Annual Lipid Update 2025

Sunday, 11/09/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Targeting PCSK9 to lower LDL-C and CVD risk – A growing array of options

Bohula Erin, Odonoghue Michelle

Will CETP inhibition PREVAIL in CVD prevention?

Nicholls Stephen

More abstracts from these authors:
Physician-Level Variation in Lipid Management for Secondary Prevention of Atherosclerotic Cardiovascular Disease: Opportunities for Practice Improvement

Nguyen Danh, Hwang Jimin, Peterson Eric, Rohatgi Anand, Joshi Parag, Khera Amit, Navar Ann Marie

Need for Testing Standardization and Improved Treatment of Elevated Lipoprotein(a) at a Large Urban Academic Medical Center

Wong Willis, Kao Cindy Hsin-yi, Schneider Ruth, Navar Ann Marie, Rohatgi Anand, Khera Amit, Joshi Parag

You have to be authorized to contact abstract author. Please, Login
Not Available